Locally Recurrent Secretory Carcinoma of the Breast with NTRK3 Gene Fusion.
Ontology highlight
ABSTRACT: Enhanced understanding of the molecular events underlying oncogenesis has led to the development of "tumor-agnostic" treatment strategies, which aim to target a tumor's genomic profile regardless of its anatomic site of origin. A classic example is the translocation resulting in an ETV6-NTRK3 gene fusion, a characteristic driver of a histologically diverse array of cancers. The chimeric ETV6-NTRK3 fusion protein elicits constitutive activation of the tropomyosin receptor kinase (TRK) C protein, leading to increased cell survival, growth, and proliferation. Two TRK inhibitors, larotrectinib and entrectinib, are currently approved for use in the metastatic setting for the treatment of advanced solid tumors harboring NTRK fusions. Here we report a rare case of recurrent secretory carcinoma of
SUBMITTER: Mortensen L
PROVIDER: S-EPMC8488779 | biostudies-literature | 2021 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA